Aspirin - CAS 50-78-2
Catalog number: 50-78-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C9H8O4
Molecular Weight:
180.16
COA:
Inquire
Targets:
Cox-2 | COX
Description:
A salicylate and irreversible COX1 and COX2 inhibitor
Brife Description:
A salicylate and irreversible COX1 and COX2 inhibitor
Appearance:
White Solid
Synonyms:
Acetylsalicylic acid; 1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
Solubility:
DMSO 36 mg/mL (199.82 mM); Ethanol 36 mg/mL (199.82 mM)
Storage:
3 years -20°C powder;6 months-80°C in solvent
MSDS:
Inquire
Quality Standard:
In-house
Quantity:
Grams-Kilos
Melting Point:
134-136°C
InChIKey:
BSYNRYMUTXBXSQ-UHFFFAOYSA-N
InChI:
1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)
Canonical SMILES:
CC(=O)OC1=CC=CC=C1C(=O)O
1.Predialysis Cardiovascular Disease Medication Adherence and Mortality After Transition to Dialysis.
Molnar MZ1, Gosmanova EO2, Sumida K1, Potukuchi PK1, Lu JL1, Jing J3, Ravel VA3, Soohoo M3, Rhee CM3, Streja E3, Kalantar-Zadeh K3, Kovesdy CP4. Am J Kidney Dis. 2016 Apr 12. pii: S0272-6386(16)00698-3. doi: 10.1053/j.ajkd.2016.02.051. [Epub ahead of print]
BACKGROUND: Medication nonadherence is a known risk factor for adverse outcomes in the general population. However, little is known about the association of predialysis medication adherence among patients with advanced chronic kidney disease and mortality following their transition to dialysis.
2.Non-enzymatic modifications of prostaglandin H synthase 1 affect bifunctional enzyme activity - Implications for the sensitivity of blood platelets to acetylsalicylic acid.
Kassassir H1, Siewiera K1, Talar M1, Stec-Martyna E2, Pawlowska Z2, Watala C3. Chem Biol Interact. 2016 Apr 12. pii: S0009-2797(16)30144-2. doi: 10.1016/j.cbi.2016.04.021. [Epub ahead of print]
Due to its ability to inhibit the blood platelet PGHS-1, acetylsalicylic acid (ASA, Aspirin®) is widely used as a preventive agent in atherothrombotic diseases. However, its beneficial effects seem to be lower in diabetic patients, suggesting that protein glycation may impair effective ASA-mediated acetylation process. On the other hand, it is proposed that ASA can prevent some of the late complications of diabetes by lowering the extent of glycation at protein free amino groups. The aim of this work was to evaluate the extents of non-enzymatic N-glycosylation (glycation) and acetylation of blood platelet PGHS-1 (COX-1) and the competition between glycation and acetylation was investigated in order to demonstrate how these two reactions may compete against platelet PGHS-1. When PGHS-1 was incubated with glycating/acetylating agents (glucose, Glu; 1.6-bisphosphofructose, 1,6-BPF; methylglyoxal, MGO, acetylsalicylic acid, ASA), the enzyme was modified in 13.
3.Endovascular Therapy for Chronic Mesenteric Ischemia.
Foley TR1, Rogers RK2. Curr Treat Options Cardiovasc Med. 2016 Jun;18(6):39. doi: 10.1007/s11936-016-0463-9.
OPINION STATEMENT: Chronic mesenteric ischemia (CMI) most commonly occurs as a consequence of multivessel atherosclerotic disease of the mesenteric vasculature. Risk factors include smoking, hypertension, dyslipidemia, and advanced age, and women are more commonly affected than men. The clinical presentation of CMI is characterized by postprandial abdominal pain and weight loss. Left untreated, patients often develop severe malnutrition. Current consensus guidelines recommend secondary prevention medications such as statins and aspirin for all patients with known atherosclerosis to reduce the risk of stroke and MI, but data specific to medical therapy in CMI are lacking. To date, no medical therapy has been proven to be effective in preventing the progression of mesenteric atherosclerosis. Revascularization through surgical bypass is associated with significant perioperative morbidity and mortality. The evolution of endovascular techniques and equipment has made catheter-based therapy a first-line option for revascularization in CMI.
4.Should aspirin be used for primary prevention of thrombotic events in patients with membranous nephropathy?
Hofstra JM1, Wetzels JF2. Kidney Int. 2016 May;89(5):981-3. doi: 10.1016/j.kint.2016.01.019.
Patients with nephrotic syndrome are at increased risk of thrombosis. The risk of venous thrombosis is particularly high in patients with nephrotic syndrome due to primary membranous nephropathy. Recent data provide evidence that these patients also have a high absolute risk of arterial thrombotic events, which is associated with the degree of hypoalbuminemia. In this commentary we discuss whether prophylactic aspirin therapy might be indicated in this patient population.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Cox-2 Products


CAS 22071-15-4 Ketoprofen

Ketoprofen
(CAS: 22071-15-4)

Ketoprofen, (RS)2-(3-benzoylphenyl)-propionic acid (chemical formula C16H14O3) is one of the propionic acid class of nonsteroidal anti-inflammatory drugs (NSAID...

CAS 853-34-9 Kebuzone

Kebuzone
(CAS: 853-34-9)

Kebuzone is a non-steroidal anti-inflammatory drug. It also has analgesic, antipyretic, and platelet-inhibitory activities. Kebuzone is a cyclooxygenase inhibit...

CAS 202409-33-4 Etoricoxib

Etoricoxib
(CAS: 202409-33-4)

A selective COX-2 inhibitor

CAS 88149-94-4 DuP-697

DuP-697
(CAS: 88149-94-4)

A selective COX-2 inhibitor

CAS 15307-79-6 Diclofenac Sodium

Diclofenac Sodium
(CAS: 15307-79-6)

A non-selective COX inhibitor with IC50 of 0.5 μg/ml and 0.5 μg/ml for COX-1 and -2 in intact cells, respectively

CAS 70374-39-9 Lornoxicam

Lornoxicam
(CAS: 70374-39-9)

A non-steroidal COX-1/COX-2 inhibitor; A nonsteroidal anti-inflammatory drug

CAS 103-90-2 Acetaminophen

Acetaminophen
(CAS: 103-90-2)

A selective COX-2 inhibitor

CAS 22161-81-5 (S)-Ketoprofen

(S)-Ketoprofen
(CAS: 22161-81-5)

A potent inhibitor of COX-1 and COX-2

Chemical Structure

CAS 50-78-2 Aspirin

Quick Inquiry

Verification code

Featured Items